Search Results
Imugene: A worldwide license to attack blood cancer
Imugene Licenses Potential for First “Allo” CAR T to be Approved in Blood Cancer
Imugene Investor Webinar | Acquisition of License for Azer-Cel Cell Therapy
'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU
First Patient dosed in Imugene's PD1-Vaxx Combination Trial
Imugene (ASX:IMU) | Webinar with Leslie Chong | 07/11/24
How Imugene is Turning Viruses into Cancer-Fighting Heroes!
A clinical stage immuno-oncology company.
Imugene Investor Presentation | Non-deal Roadshow 2023 Australia
Imugene talks VAXINIA MAST trial and corporate ambition
Stocks of the Hour: AML3D, Imugene, Loyal Lithium
The stock of the day is Imugene (IMU)
